<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093587</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000389241</org_study_id>
    <secondary_id>UCLA-0402009-01</secondary_id>
    <secondary_id>GENZ-SMC-101-1026</secondary_id>
    <nct_id>NCT00093587</nct_id>
  </id_info>
  <brief_title>Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia</brief_title>
  <official_title>Pilot Trial of Two Dose Levels of Thymoglobulin® as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor (MRD) Stem Cell Transplant With Cyclosporine (CsA) as Posttransplant Graft vs Host Disease (GvHD) Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow&#xD;
      transplant or peripheral blood stem cell transplant helps stop the growth of cancer cells. It&#xD;
      also helps stop the patient's immune system from rejecting the donor's stem cells. When the&#xD;
      healthy stem cells from a donor are infused into the patient they may help the patient's bone&#xD;
      marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the&#xD;
      transplanted cells from a donor can make an immune response against the body's normal cells.&#xD;
      Giving antithymocyte globulin before transplant and cyclosporine after transplant may stop&#xD;
      this from happening.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well giving antithymocyte globulin&#xD;
      together with cyclosporine works in preventing graft-versus-host disease in patients who are&#xD;
      undergoing chemotherapy with or without radiation therapy followed by donor stem cell&#xD;
      transplant for acute lymphoblastic leukemia or acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the incidence of acute graft-vs-host disease (GVHD) within the first 100 days&#xD;
           after transplantation in patients with acute lymphoblastic leukemia or acute myeloid&#xD;
           leukemia treated with a myeloablative conditioning regimen comprising cyclophosphamide&#xD;
           (with or without radiotherapy) and low- vs high-dose anti-thymocyte globulin followed by&#xD;
           allogeneic HLA-matched related stem cell transplantation and cyclosporine.&#xD;
&#xD;
        -  Compare the incidence of serious adverse events within the first 100 days after&#xD;
           transplantation in patients treated with these regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare 100-day and 6-month survival in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the severity of acute GVHD in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the incidence of culture-proven infections at 100 days and 6 months after&#xD;
           transplantation in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the incidence of mucositis, in terms of presence, severity, and duration, in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare the number of days on opiate drugs within the first 30 days after&#xD;
           transplantation in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the time to engraftment in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the incidence of hospitalization within the first 6 months after&#xD;
           transplantation, in terms of length of initial stay, cumulative total days, and number&#xD;
           of hospitalizations, in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the relapse rate and time to relapse in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the incidence and severity of chronic GVHD between 100 days and 6 months after&#xD;
           transplantation in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a pilot, randomized, open-label, multicenter study.&#xD;
&#xD;
        -  Conditioning: All patients receive a standard myeloablative-conditioning regimen that&#xD;
           contains cyclophosphamide IV over 2 hours per center regimen, typically on days -6 to&#xD;
           -3. Patients also undergo total body irradiation OR receive busulfan.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis (as part of conditioning): Patients are&#xD;
           randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive low-dose anti-thymocyte globulin IV over 4-8 hours on days&#xD;
                -3 to -1.&#xD;
&#xD;
             -  Arm II: Patients receive high-dose anti-thymocyte globulin IV over 4-8 hours on&#xD;
                days -5 to -1.&#xD;
&#xD;
        -  Allogeneic hematopoietic stem cell transplantation: Patients in both arms undergo&#xD;
           allogeneic peripheral blood stem cell or bone marrow transplantation on day 0.&#xD;
&#xD;
        -  Post-transplantation GVHD prophylaxis: Patients in both arms receive cyclosporine IV&#xD;
           over 1-4 hours or orally twice daily beginning on day -1 and continuing until&#xD;
           approximately day 60 followed by tapering doses until day 180 in the absence of GVHD.&#xD;
&#xD;
      Patients are followed at 7, 14, 21, 30, 100, and 180 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-60 patients (15-30 per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2004</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia&#xD;
&#xD;
               -  In first complete remission or second complete remission&#xD;
&#xD;
          -  Secondary AML allowed&#xD;
&#xD;
          -  HLA-A, -B, and -DRB1 identical related donor available AND must be fully matched at&#xD;
             Class II by high-resolution molecular HLA typing (at least 4 digits)&#xD;
&#xD;
          -  Currently receiving a myeloablative conditioning regimen that includes&#xD;
             cyclophosphamide&#xD;
&#xD;
               -  All patients from a center should receive the same conditioning regimen&#xD;
                  throughout the study&#xD;
&#xD;
               -  No fludarabine or other purine analogues (e.g. cladribine or pentostatin) as part&#xD;
                  of conditioning regimen&#xD;
&#xD;
          -  No uncontrolled CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 55&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 mg/dL&#xD;
&#xD;
          -  ALT and/or AST ≤ 3 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction &gt; 40%&#xD;
&#xD;
          -  No severe cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known contraindication to administration of rabbit anti-thymocyte globulin&#xD;
&#xD;
          -  No current drug or alcohol abuse&#xD;
&#xD;
          -  No significant medical or psychosocial problem or unstable disease state (including,&#xD;
             but not limited to, morbid obesity) that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior or concurrent bone marrow transplantation from a donor who has positive&#xD;
             serology for HIV, hepatitis B virus, hepatitis C virus, or syphilis&#xD;
&#xD;
          -  No IV immunoglobulin prior to engraftment&#xD;
&#xD;
          -  No concurrent ex vivo engineered or processed graft (CD34+ enrichment or T-cell&#xD;
             depletion)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior or concurrent methotrexate for graft-vs-host disease prophylaxis&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior experimental agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
               -  Enrollment in investigational studies (i.e., anti-microbial agents) allowed only&#xD;
                  for life threatening events or after exhausting other treatment modalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary J. Schiller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

